WALTHAM, MA, August 5, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received approval from the U.S. Food and Drug Administration (“FDA”) to initiate its follow-on pilot study for punctate epitheliopathies (“PE”). The…
Agency Provides Guidance That Positive Data From Upcoming Phase 3 Trial Sufficient to Support NDA FilingWALTHAM, Mass., May 4, 2015 (GLOBE NEWSWIRE) — Eyegate Pharmaceuticals, Inc. (OTCQB:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced receipt…
WALTHAM, Mass., May 14, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for the continued listing of its securities on The Nasdaq Capital Market (“Nasdaq”). The Company’s continued listing on Nasdaq is subject to the Company evidencing…
Patent to Provide Broad Coverage for EyeGate II® Delivery System with Pre-filled Drug Applicator Also, Patent Covering Proprietary Dexamethasone Phosphate Pharmaceutical Formulation Granted WALTHAM, Mass., Oct. 15, 2015 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases…
WALTHAM, MA, August 12, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received positive feedback following its pre-IND meeting with the U.S. Food and Drug Administration (“FDA”) and has been provided a path…
Data Anticipated Q1 2017 WALTHAM, Mass., Jan. 19, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that the first patient was enrolled in the Company’s confirmatory Phase 3 clinical trial…
WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the first patient in its follow-on pilot study for punctate epitheliopathies (“PE”). The study will use the Ocular Bandage Gel…
WALTHAM, MA, November 22, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has received select topline data, specifically the primary endpoint, demonstrating superiority over standard-of-care in its corneal wound repair pivotal study using the…
WALTHAM, Mass., August 26, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 50% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel…
WALTHAM, Mass., Sept. 16, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 75% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel…